Streetbeat News

Price Targets

ARHS

In the last 3 months, 5 analysts have offered 12-month price targets for Arhaus (NASDAQ:ARHS), with an average price target of $12.4, a high of $15.00, and a low of $9.00. The average price target has increased by 0.57% over the past month.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 4:00 pm

GWRE

Guidewire Software shares are trading higher after Stifel upgraded the stock from Hold to Buy and raised its price target from $75 to $85.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 3:55 pm

SAIA

Evercore ISI Group upgraded Saia stock from In-Line to Outperform and raised its price target from $298 to $360, causing shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 3:48 pm

PDD

A whale has taken a bullish stance on PDD Holdings (NASDAQ:PDD), with 53% of investors opening trades with bullish expectations and 46% with bearish. Whales have been targeting a price range of $35 to $105 for PDD Holdings over the last 3 months. The stock is currently up 3.66% at $72.13, and RSI indicators suggest it may be approaching overbought. Analysts maintain various ratings and price targets on PDD Holdings.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 3:48 pm

NKTX

HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on Nkarta (NASDAQ:NKTX) but lowers the price target from $30 to $16.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 3:41 pm

NKTX

Needham analyst Gil Blum maintains a Buy rating on Nkarta (NASDAQ:NKTX) but lowers the price target from $26 to $19.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 3:40 pm

XOM

A whale investor has taken a bearish stance on Exxon Mobil (NYSE:XOM), with 62% of detected trades having bearish expectations. Whales have been targeting a price range of $95 to $120 for Exxon Mobil over the last 3 months. RBC Capital downgraded its action to Sector Perform with a price target of $125, while Piper Sandler maintained their Overweight rating with a price target of $127.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 3:32 pm

AZN

AstraZeneca's stock is trading at $71.26 after a 0.66% drop, with a P/E ratio of 47.5, higher than the pharmaceutical industry's aggregate P/E ratio of 35.72. This could indicate overvaluation or better future performance compared to its industry group.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 3:17 pm

CARA

Stifel analyst Annabel Samimy has reiterated a Buy rating on Cara Therapeutics (NASDAQ:CARA) and maintained a $28 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 3:12 pm

BDTX

Wedbush analyst Robert Driscoll upgraded Black Diamond Therapeutic (NASDAQ:BDTX) from Neutral to Outperform and announced a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 3:09 pm